
ICC/IF analysis of NIH/3T3 cells using GTX30025 ADAM9 antibody. Oragne : Primary antibody Blue : DAPI Dilution : 1:50
ADAM9 antibody
GTX30025
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetADAM9
Overview
- SupplierGeneTex
- Product NameADAM9 antibody
- Delivery Days Customer7
- Application Supplier NoteWB: 1:500 - 1:2000. ICC/IF: 1:50 - 1:200. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID8754
- Target nameADAM9
- Target descriptionADAM metallopeptidase domain 9
- Target synonymsCORD9, MCMP, MDC9, Mltng, disintegrin and metalloproteinase domain-containing protein 9, ADAM metallopeptidase domain 9 (meltrin gamma), cellular disintegrin-related protein, cone rod dystrophy 9, metalloprotease/disintegrin/cysteine-rich protein 9, myeloma cell metalloproteinase
- HostRabbit
- IsotypeIgG
- Protein IDQ13443
- Protein NameDisintegrin and metalloproteinase domain-containing protein 9
- Scientific DescriptionThis gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The protein encoded by this gene interacts with SH3 domain-containing proteins, binds mitotic arrest deficient 2 beta protein, and is also involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. Several alternatively spliced transcript variants have been identified for this gene. [provided by RefSeq, Jul 2010]
- ReactivityHuman, Mouse, Rat
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC41116161
References
- Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma. Cheng WC et al., 2021, TheranosticsRead this paper
- The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Kim JM et al., 2014 Dec, Mol Cancer TherRead this paper







